New Combined Therapy for Mycoplasma Pneumonia in Children

Mycoplasma pneumoniae pneumonia (MPP) is a common respiratory infection in children, often associated with severe complications and a high risk of mortality. The refractory form of this disease, refractory Mycoplasma pneumoniae pneumonia (RMPP), resists standard macrolide treatments and presents with persistent and severe symptoms. Identifying new therapeutic solutions is therefore a priority.  

To address these challenges, the combination of azithromycin with intravenous immunoglobulins (IVIG) has emerged as a promising strategy for the effective treatment of RMPP. This study evaluates the latest evidence regarding the efficacy and safety of this combined approach.  

Azithromycin-IVIG Combination: Enhanced Therapeutic Efficacy?